PAK4 phosphorylates p53 at serine 215 to promote liver cancer metastasis by Ng, IOL et al.
Title PAK4 phosphorylates p53 at serine 215 to promote liver cancermetastasis
Author(s) Xu, HT; Lai, WL; Liu, HF; Wong, LLY; Ng, IOL; Ching, YP
Citation Cancer Research, 2016, v. 76 n. 19, p. 5732-4572
Issued Date 2016
URL http://hdl.handle.net/10722/231428
Rights This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
 1
PAK4 phosphorylates p53 at serine 215 to promote liver cancer metastasis 
 
Hai-Tao Xu1*, Wai-Lung Lai1*, Heong-Fai Liu1, Leo Lap-Yan Wong1, Irene Oi-Lin 
Ng2,3 and Yick Pang Ching1,3,4,5 
 
1School of Biomedical Sciences and 2Department of Pathology, Li Ka Shing Faculty 
of Medicine, and 3State Key Laboratory for Liver Research, 4Cancer Research Center, 
The University of Hong Kong, Hong Kong, China  
5Correspondence and requests for materials should be addressed to Y.P.C. (email: 
ypching@hku.hk) 
*These authors contributed equally  
 
Running title: PAK4 regulates p53 by phosphorylation 
 
Keywords: Kinase, HCC, metastasis, phosphorylation, p53  
 
Grant Support: The Hong Kong Health and Medical Research Fund (No. 02131756) 
(YPC). 
 
Word count:  5995; 6 figures and 1 table  
 2
Abstract 
 
P21-activated protein kinase 4 (PAK4), which is a member of the Group II 
PAK protein kinase family, has been shown to play significant roles in cellular 
signaling pathways including cell migration, cell survival and cellular transformation. 
Overexpression of PAK4 has been reported in cancers, but the oncogenic properties of 
PAK4 are not well defined. Here we showed that PAK4 mRNA and protein were 
overexpressed in clinical hepatocellular carcinoma (HCC) samples. 
Clinicopathological correlation analysis showed that overexpression of PAK4 
significantly associated with aggressive and metastatic tumor phenotypes. Also, a 
nuclear isoform of PAK4, which lacked the exon two, was isolated during our 
characterization of PAK4. Using stable PAK4 overexpressing and knockdown clones, 
we showed that PAK4 was required for HCC cell migration. To understand how 
PAK4 promotes hepatocarcinogenesis, we observed that PAK4 could directly 
phosphorylate p53 at serine residue 215. Functionally, the S215 phosphorylation not 
only attenuated the transactivating activity of p53, but also inhibited the p53-mediated 
suppression of HCC cell invasion. Taken together, our data showed that PAK4 was 
frequently overexpressed in HCCs and overexpression of PAK4 promotes HCC 
metastasis via regulating p53 by phosphorylation. 
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Introduction 
 The p21-activated serine/threonine protein kinases (PAKs) family plays a 
critical role in controlling cytoskeletal dynamics and is involved in several cellular 
processes including cellular motility, survival and hormonal signaling. PAKs function 
as downstream effectors of the small Rho GTPases Rac1 and Cdc42 (1). PAK4 
belongs to the Group II PAKs. Unlike Group I PAKs, the association of an active, 
GTP-bound Cdc42 or Rac does not enhance the autophosphorylation as well as the 
activity of PAK4 (2). However, a recent study showed that PAK4 contains a pseudo-
substrate domain, which contributes significantly to its autoregulation (3). For the 
regulation of cytoskeletal dynamics, it has been demonstrated that PAK4 potentiated 
the formation of filopodia induced by the constitutively active Cdc42 (2). A 
constitutively active form of PAK4 (S445N) could induce cell rounding and 
dissolution of stress fiber (4). Overexpression of PAK4 has been reported to promote 
ovarian and prostatic cancers progression (5,6). In addition, a recent genome wide 
study of the miRNA expression profile in HCC has identified miR-199a/b-3p, which 
targeted PAK4 to promote hepatocarcinogenesis (7). However, the detail molecular 
mechanism by which PAK4 promotes cancer formation remains largely unknown. 
In this study, we evaluated the PAK4 mRNA and protein expression levels in 
paired clinical HCC samples. With the availability of an exon 2-deleted PAK4 
isoform (PAK4β), we delineated a nuclear exporting signal that dictates the 
localization of PAK4. To understand the mechanism by which PAK4 exerts on 
carcinogenesis, we demonstrated that p53 was a direct substrate of PAK4 and the 
phosphorylation of p53 by PAK4 not only inhibits the p53 activity, but also promotes 
cell migration. Taken together, our data has revealed a novel mechanism by which 
PAK4 enhances HCC metastasis by phosphorylation of p53.  
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Materials and Methods 
Antibodies and chemicals. Rabbit anti-phospho-p53 (S215) antibody was raised 
against a synthetic peptide RNTFRHpSVVVPYE (a.a.209-221) (Applied Biological 
Materials, Richmond, BC, Canada). Cisplatin and etoposide were from Merck KGaA 
(Darmstadt, Hesse, Germany). All chemicals were from Sigma-Aldrich (St. Louis, 
MO, USA) unless otherwise stated. 
Cell culture Human HCC cell lines Hep3B, HepG2, HLE, Huh-7 and PLC/PRF/5, 
cervical adenocarcinoma cell line HeLa and embryonic kidney cell line HEK293T 
were purchased from the American Type Culture Collection (Manassas, VA, USA). 
The authentication of these cell lines was assured by the provider by cytogenetic 
analysis. Human HCC cell lines H2M and H2P were from Guan XY, HKU. 
MHCC97L cell line was from Liver Cancer Institute, Fudan University, China. 
SMMC-7721, Bel-7402 and LO2 cell lines were gifts from Shanghai Institute of 
Biochemistry and Cell Biology, Chinese Academy of Sciences. All cell lines were 
regularly authenticated by morphologic observation under microscopy and tested for 
the absence of mycoplasma contamination. All cells were maintained in DMEM 
(GIBCO-BRL, Grand Island, NY, USA) with 10% fetal bovine serum, 100U/ml 
penicillin and 100µg/ml streptomycin. Stable overexpressing or knockdown clones 
were selected by medium with 0.8mg/ml of G418 (Invitrogen, Carlsbad, CA, USA).  
Reverse transcription-PCR  Quantitative RT-PCR (qRT-PCR) was performed as 
described previously (8). The sequence of Taqman probe (Applied Biosystems, Foster 
City, CA, USA) for PAK4 was 5’-GCGGCGCCGAGCCGATGAGTAACCC-3’. For 
RT² Profiler PCR Array Human Tumor Metastasis, data was analyzed using the 
software at PCR Array Data Analysis Web portal (Qiagen, Germantown, MD, USA), 
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according to manufacturer’s protocol. PCR amplification for both PAK4 and β-actin 
was performed at the annealing temperature of 57°C for 25 cycles.  
Western Blotting, GST affinity pull-down and luciferase reporter assays The 
assays were performed as described previously (8). Fractionation was performed 
using NucBuster Protein Extraction Kit (Novagen, Madison, WI, USA) according to 
manufacturer’s protocol. 
Co-immunoprecipitation Procedure was described previously (8). Cells were lysed 
with NETN buffer with protease inhibitor cocktail (Roche Diagnostics GmbH, 
Mannheim, Germany). Antibodies used for immunoprecipitation and immunoblotting 
were indicated in the figures.  
Colony formation, Transwell migration, Matrigel invasion and wound healing 
assays The assays were performed as described previously (8). For wound healing 
assay, cells were pre-treated with 10μg/ml mitomycin C for 3 hours. Three 
independent experiments were performed for each of the assays. 
Confocal microscopy.  Procedure was described previously (8). Images were 
captured by Carl Zeiss LSM 510 microscope (Carl Zeiss Microimaging Inc., 
Thornwood, NY, USA) at the Faculty Core Facility, HKU. 
Immunohistochemistry (IHC) staining. The IHC staining for PAK4 (1:100 dilution) 
and phospho-PAK4 (S474) (1:50 dilution) was performed as described previously (8).  
Electrophoretic mobility shift assay (EMSA). Nuclear extract was prepared as 
described previously with some modifications (9). The nuclear pellet was extracted 
with cold buffer (20mM HEPES, pH 7.9, 400mM NaCl, 1mM EDTA, 1mM EGTA, 
1mM DTT and protease inhibitor cocktail). The nuclear extract was incubated with 
the 32P-labeled oligonucleotide encoding the p53 consensus DNA binding site (5’-
TACAGAACATGTCTAAGCATGCTGGGGACT-3’) (Santa Cruz Biotechnology, 
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Dallas, TX, USA). Competition for p53 DNA binding was performed with unlabeled 
(X100) or mutant oligonucleotides (5’-
TACAGAATCGCTCTAAGCATGCTGGGGACT-3’). The protein-DNA complexes 
were separated by electrophoresis through a 5% native polyacrylamide gel.  
In vitro kinase assay. The assay was performed as described previously (8). The 
kinase reaction was performed at 30°C for 20 minutes with γ-32P-ATP. 
Statistical analyses.  Student t test and χ2 or Fisher’s exact test analyzed by SPSS 18 
(SPSS Inc, Chicago, IL, USA) were used as appropriate. Tests were considered 
significant when P < 0.05. 
 
Results 
PAK4 was frequently overexpressed in HCC tumor tissue samples. PAK4 
overexpression has been reported in various cancerous cell lines (10,11). However, 
little is known about the expression status of PAK4 in primary cancer. To examine the 
expression of PAK4 in HCC, the PAK4 transcript in HCC and its corresponding 
nontumorous liver tissues was determined by qRT-PCR. After normalization with 18S 
rRNA, 60.3% (35/59 cases) of the HCC had a higher expression of PAK4 (T/NT > 2) 
compared with the corresponding nontumorous tissues (P < 0.0001, Wilcoxon 
matched pair test; Fig. 1A). To corroborate the upregulation of PAK4 protein in HCCs, 
we examined the PAK4 protein expression by Western blotting. Overexpression of 
PAK4 protein (T/NT > 2) was observed in the HCC cases with PAK4 transcript 
upregulation, whereas PAK4 transcript that had a similar expression level (Case 211) 
showed no significant difference in the PAK4 protein level (Fig. 1B). To further 
confirm the overexpression of PAK4 in tumor cells, IHC staining was performed 
using total and phospho-specific (serine-474) anti-PAK4 antibodies. Interestingly, 
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strong cytoplasmic staining was observed for total PAK4 and strong nuclear staining 
was observed for p-PAK4 (S474) in HCC cells (Fig. 1C), indicating that active form 
of PAK4 preferentially localizes to the nuclei of HCC cells. 
Overexpression of PAK4 transcript was associated with more aggressive tumor 
behavior. To understand how PAK4 expression is related to HCC, 
clinicopathological association analysis was performed. Overexpression of PAK4 was 
significantly correlated with the presence of venous invasion, liver invasion, poorer 
tumor cell differentiation (classified according to Edmondson grading) and the late 
pTMN stage, suggesting a more aggressive tumor behavior and a higher incidence of 
metastasis (Table 1). However, no significant correlation was found between PAK4 
overexpression with patient survival rates by the log-rank test (data not shown). 
Overexpression of PAK4 promoted HCC cell migration. To study the functional 
role of PAK4 in HCC, two stable PAK4 overexpressing clones (PAK4-C1 and -C2) 
and two vector control clones (GFP-C1 and -C2) were established in the HCC cell 
line SMMC-7721, which has a low endogenous level of PAK4 (Fig. 5D). After 
confirming the stable expression of PAK4 (Fig. 2A, top panel), the cell proliferation 
rate of stable PAK4 overexpressing clones were compared with vector controls, but 
no significant difference was observed (Supp. Fig. 1B). Interestingly, we observed 
that stable expression of PAK4 induced a morphological change, resulting in 
elongated and accumulated spiky structures at the cell peripheries (Fig. 2A). To 
address whether the stable PAK4 overexpressing clones have an increased motility, 
Transwell migration and wound healing assays were performed. In the Transwell 
migration assay, the number of migrated cells in stable PAK4 overexpressing clones 
was remarkably increased compared with the control clones (Fig. 2B). Consistently, 
in the wound healing assay, wound closure of the stable PAK4 overexpressing clones 
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was significantly faster than that of the control clones (Fig. 2C). To assess the 
invasiveness of stable PAK4 overexpressing clones, Matrigel invasion assay was 
performed. As shown in Fig. 2D, the number of invaded cells in stable PAK4 
overexpressing clones was significantly higher than that of the control clones. Overall, 
these results indicated that PAK4 not only promotes HCC cell motility, but also 
enhances the invasiveness of HCC cells. 
Knockdown of PAK4 inhibited HCC cell migration. To further confirm the effect 
of PAK4 on HCC cell motility, we adopted a loss-of function approach to specifically 
knockdown PAK4 using the vector-based short hairpin RNA (shRNA). The HCC cell 
line, HLE, was chosen for the establishment of stable PAK4 knockdown clones due to 
its high endogenous PAK4 protein level (Fig. 5D). Consistently, the migration rate 
measured by Transwell migration assay was significantly decreased in the stable 
PAK4 knockdown clones (Fig. 2E) while no significant differences were observed for 
the proliferation rate (data not shown). 
Exon 2 conferred cytoplasmic localization of PAK4. A recent study has shown that 
another Group II PAK family member PAK5 contains a nuclear exporting signal 
(NES), which may have an important role in the anti-apoptotic activity of PAK5 (12). 
In the IHC staining, predominant nuclear staining of phospho-PAK4 was observed in 
the HCC cells. Moreover, during the cloning of PAK4, we obtained from Japan 
Kazusa DNA Research Institute an isoform of PAK4, in which the complete exon 2 
(a.a.69-221) was missing. Hence, we designated this form as PAK4β and the previous 
full-length form of PAK4 as PAK4α in the remaining discussion. To detect the 
existence of PAK4β, RT-PCR were performed on an immortalized hepatocyte cell 
line (LO2) and a panel of HCC cell lines using a pair of PCR primers derived from 
exon 1 and 3 sequences. The result showed that the transcripts of both PAK4α and β 
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were amplified in all the HCC cell lines examined (Supp. Fig. 1A). PAK4β protein 
was also detectable in all the HCC cell lines tested except LO2 and H2M by Western 
blotting (Fig. 5D), confirming the presence of PAK4β in HCC cells. When we studied 
the subcellular localization of PAK4, GFP-tagged PAK4α was found mainly localized 
in the cytoplasm, whereas PAK4β was localized in the nuclei (Fig. 3A). Treatment of 
cells with leptomycin B (LMB), a specific inhibitor for the nuclear export machinery, 
caused the cytoplasmic PAK4α to translocate into nuclei (Fig. 3A). Such effect was 
not cell-line specific because similar translocation pattern was also observed in other 
HCC cells, HLE and SMMC-7721 (data not shown). To further confirm the 
subcellular localization of endogenous PAK4, we performed cellular fractionation 
assay. PAK4α was mainly found in the cytoplasmic fraction while the nuclear fraction 
contained a shorter polypeptide, corresponding to the size of PAK4β, which was also 
recognized by the polyclonal anti-PAK4 antibody targeting the N-terminal of PAK4 
(Supp. Fig. 2A). In addition, the constitutively active form of PAK4α (S445N) also 
translocated to the nuclei in the presence of LMB (Fig. 3B), indicating that the NES 
signal operated effectively in activated PAK4. To identify the NES sequence, we 
subjected the amino acid sequence of PAK4α to the NES search engine, 
PATTINPROT. Six potential NES sequences were identified, but only one locates in 
the exon 2, corresponding to the a.a.82-94 of PAK4α (Supp. Fig. 2B). To consolidate 
the autonomy of NES sequence, we fused the NES sequence to the C-terminal of GFP 
protein. The fusion protein was observed to solely localize in the cytoplasm and 
treatment with LMB induced re-localization of the fusion protein throughout the 
whole cell (Supp. Fig. 2C), suggesting that a.a.82-94 is a functional NES sequence. 
The critical residues for the NES signal were further characterized by mutating the 
conserved residues lysine 82 (L82) and valine 94 (V94) to alanine. The result showed 
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that single substitution of L82A or V94A had a limited effect on the re-localization of 
the mutant proteins to the nuclei (Fig. 3C). However, substitutions of both L82 and 
V94 to alanine (PAK4 LVAA) completely abolished the cytoplasmic localization 
pattern (Fig. 3C). Furthermore, the fractionation assay confirmed that the PAK4 
LVAA was found in the nucleus, whereas the PAK4α WT was mainly localized in the 
cytoplasm (Fig. 3D).  
PAK4 interacted with p53 and phosphorylated p53 at serine 215. A recent study 
using PAK chemical inhibitor PF-3758309 demonstrated that PAK4 may act upstream 
of p53 signaling, but the detailed mechanism remains elusive (13). To investigate 
whether p53 is a substrate of PAK4, in vitro PAK4 kinase assay was performed. As 
shown in Fig. 4A, both WT and a serine-15-to-alanine (S15A) mutant of GST-fused 
p53 (GST-p53) were phosphorylated to a similar extent by the bacterially purified 
His-tagged PAK4α (His-PAK4), indicating that p53 is a direct phosphorylation 
substrate of PAK4, but PAK4 phosphorylation of p53 did not occur at S15, which is 
important for the regulation of p53 protein stability (14). The specificity of PAK4 
kinase activity was demonstrated by the phosphorylation of a specific substrate 
control, GST-PAK4tide (Fig. 4A) (8). To map the PAK4 phosphorylation site on p53, 
we generated three truncation mutants of p53, namely M1, M2 and M3, according to 
the transactivation (TAD), DNA binding (DBD) and C-terminal regulatory (CTD) 
domains of p53 (Fig. 4B). Although the construct of truncation mutant carrying a.a.1-
92 had been generated, the expressed protein was completely insoluble during 
purification. Hence, the three purified truncation mutants were used in the PAK4 
kinase assay. As shown in Fig. 4C, His-PAK4 phosphorylated significantly the 
mutants M1 and M2, but not M3, suggesting that the PAK4 phosphorylation site(s) 
may be located in the p53 DBD. Using GST affinity pull-down assay, we showed that 
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M2, but not M3, directly associated with PAK4 with a high affinity (Fig. 4D). To 
answer whether PAK4 and p53 interact intracellularly, co-immunoprecipitation was 
performed. As expected, p53 WT and M2 were detected in the PAK4α 
immunoprecipitate (Fig. 4E). Interestingly, we observed that the PAK4 LVAA 
revealed a stronger interaction with p53 WT and M2 (Fig. 4E, lanes 15 and 16, 
respectively) than PAK4α. Similar results were also obtained in the reciprocal co-
immunoprecipitation (Fig. 4E, lanes 24 to 27). Based on the PAK4 phosphorylation 
site consensus sequence: R-X-S-W/I/V/Y-A/Y-S (R: arginine; X: any; S: serine; 
W/I/V/Y: tryptophan/isoleucine/valine/tyrosine; A: alanine) (15), a potential PAK4 
phosphorylation site was identified at the serine residue 215 (S215) within the DBD, 
which is also a phosphorylation site for Aurora kinase A (16). To verify the S215 
phosphorylation by PAK4, we generated a non-phosphorylatable mutant by 
substituting S215 with an alanine residue (S215A) and performed the in vitro kinase 
assay. While the p53 WT was significantly phosphorylated by PAK4α and Aurora 
kinase A, mutation of S215 completely abolished the phosphorylation (Fig. 4F), 
strongly indicating that the S215 is a putative PAK4 phosphorylation site. 
PAK4 phosphorylated the S215 site of p53 within the cells. To elucidate whether 
the S215 phosphorylation occurs endogenously, we co-transfected the expression 
constructs of Myc-p53 WT or S215A mutant together with PAK4α WT or LVAA 
mutant into HCC cells. After immunoprecipitation, their phosphorylation status was 
examined using an anti-phospho-serine antibody. Compared with the vector control, 
ectopic expression of PAK4α WT and LVAA could significantly increase the 
phosphorylation of p53 by 3.0 and 16.3 folds, respectively (Fig. 5A), whereas the 
signal was completely abolished on the p53 S215A mutant even in the presence of 
PAK4α WT or LVAA, confirming that S215 is an intracellular PAK4 
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phosphorylation site. To specifically detect the phosphorylation of S215, a phospho-
specific antibody was raised. The specificity of the anti-p-p53 (S215) antibody was 
verified by in vitro PAK4 kinase assay. As shown in Fig. 5B, WT but not the S215A 
mutant of p53 was recognized by the anti-p-p53 (S215) antibody incubated with His-
PAK4α (lanes 3 and 5, respectively) or His-Aurora kinase A (lanes 7 and 8, 
respectively). Next, we sought to detect the endogenous phosphorylation of p53 by 
transfecting SMMC-7721 cells with constructs expressing p53 WT or S215A  
together with PAK4α. The anti-p-p53 (S215) antibody only detected the signals in 
cells co-expressing PAK4α and p53 WT, but not in cells co-expressing the S215A 
mutant (Fig. 5C). Using anti-p-p53 (S215) antibody, we detected strong S215 
phosphorylation signal in HCC cell lines with high endogenous PAK4 expression, 
including HepG2, HLE, H2P and MHCC97L (Fig. 5D). However, silencing of PAK4 
expression by stably shRNA or transiently siRNA in knockdown HLE cells 
remarkably lowered the S215 phosphorylation signal (Fig. 5E and Supp. Fig. 3, 
respectively), strongly suggesting that the S215 of p53 is an endogenous PAK4 
phosphorylation site. 
PAK4 phosphorylation attenuated p53 tumor suppressive, transactivating and 
DNA binding activities. To evaluate whether PAK4 phosphorylation on p53 affects 
cell growth, colony formation assay was performed. As shown in Fig. 6A, a 
significant increase in the number of colonies was found in cells transfected with the 
S215D mutant compared with WT or S215A mutant, suggesting that phosphorylation 
of S215 attenuates p53 growth suppressor activity. To examine if PAK4 
phosphorylation has an impact on the transactivating activity of p53, p53-responsive 
luciferase reporter assays were performed. While co-transfecting with PAK4α 
significantly inhibited the transactivating activity of p53 WT in a dose-dependent 
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manner, similar inhibition was not observed in the S215A and S215D mutants, and 
the S215D mutation led to a significant reduction in p53 transactivating activity (Fig. 
6B). To further evaluate if nuclear localization of PAK4 is essential for the inhibition 
of p53 activity, PAK4 LVAA was co-transfected with p53-responsive luciferase 
reporter into HCC cells. The PAK4 LVAA exhibited a much potent inhibitory effect 
on p53 transactivating activity compared with WT (Fig. 6C), suggesting that the 
nuclear localization of PAK4 augmented the inhibition of p53 activity. Then, we 
wondered if the phosphorylation of S215, which located within the p53 DBD domain, 
would affect the DNA binding activity of p53. Using the EMSA, we compared the 
DNA binding affinity of p53 isolated from the PAK4/p53 and PAK4 LVAA/p53 co-
transfected lysates. Co-transfection of PAK4 and PAK4 LVAA significantly 
decreased the ability of p53 to form a complex with the p53 oligonucleotides by about 
10% and more than 30%, respectively (Fig. 6D, lane 5 and 6), implicating that PAK4 
phosphorylation lowered the ability of p53 to bind DNA. Treatment of SMMC-7721 
cells with two chemotherapeutic agents, cisplatin and etoposide, significantly 
suppressed the colony formation and upregulated p21CIP1/Waf1 expression (Fig. 6E). 
However, both of these effects were alleviated by the ectopic expression of PAK4, 
and were completely abolished by the expression of PAK4 LVAA, without 
significantly affecting the p53 protein level. Since our clinicopathological features 
analysis indicated that overexpression of PAK4 was associated with a more metastatic 
phenotype, we sought to examine the impact of p53 phosphorylation on cancer 
metastasis. Stable p53 WT, S215A and S215D mutants overexpressing clones were 
established with SMMC-7721 cells, and were confirmed by Western blot (Fig. 6F). 
Using Transwell migration (Fig. 6F) and Matrigel invasion (Fig. 6G) assays, we 
demonstrated that overexpression of WT and S215A significantly reduced the number 
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of migratory and invasive cells, whereas the S215D mutant had negligible effects. 
However, transient transfection of PAK4α into the stable p53 WT clone could 
partially rescue the migration suppressive effect of p53 (Fig. 6H), whereas the S215A 
mutant could not be reversed by PAK4α, indicating that p53 could suppress HCC cell 
invasion but was abolished by PAK4 phosphorylation. Similar phenomenon was also 
observed in PAK4 knockdown HLE cells. Transiently expression of the S215A 
mutant, but not WT, significantly suppressed the vector clone migration, whereas 
expression of WT and S215A showed no significant difference on cell migration in 
stable PAK4 knockdown clones, suggesting that the p53-mediated inhibition of cell 
migration is PAK4 and S215 phosphorylation dependent (Suppl. Fig. 4A). 
To search the genes responsible for the attenuation of cell migration and 
invasion exerted by p53, a qRT-PCR array was performed using the RNA extracted 
from the stable p53 overexpressing cells. Among the 84 metastasis-related genes 
screened, the transcript level of three metastasis suppressors, cadherin 6 (CDH6), 
cyclin-dependent kinase inhibitor 2A (CDKN2A) and kisspeptin-1 receptor (KISS1R), 
was significantly downregulated in the S215D mutant compared with WT and S215A 
mutant cells, whereas two metastasis enhancers, fibroblast growth factor receptor 4 
(FGFR4) and vascular endothelial growth factor A (VEGFA), were significantly 
upregulated in the S215D mutant cells (Fig. 6I). Consistently, the protein levels of the 
three metastasis suppressors were downregulated in the stable S215D mutant 
compared with WT and S215A mutant cells (Fig. 6J), indicating that p53 may 
suppress cancer metastasis via regulating specific metastasis-related genes. In the high 
endogenous PAK4 expressing HCC cell lines, at least one, if not all, of these 
metastatic suppressors were observed to be differentially expressed, supporting the 
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notion that the regulation of p53 by PAK4 is relevant to cancer metastasis (Supp. Fig. 
4B).  
 
Discussion 
Overexpression of PAK4 has been demonstrated in various cancer cell lines 
and clinical samples, such as ovarian and gastric cancers (6,10,17). Although 
evidences have shown that PAK4 is involved in the hepatocyte growth factor (HGF), 
c-Src/epidermal growth factor (EGF) and Smad2/3 signaling pathways, the molecular 
mechanism by which PAK4 promotes cancer formation is still far from clear (6,17,18). 
In this study, we demonstrated that PAK4 transcript and protein are frequently 
overexpressed in HCCs (Fig. 1). Clinicopathological analysis revealed that 
overexpression of PAK4 mRNA is significantly associated with poorer prognosis with 
high incidence of metastasis (Table 1). Consistently, we observed that stable PAK4 
overexpression in HCC cells induces morphological changes that are likely to be 
related to the aberrant regulation of actin cytoskeletal structure, as illustrated by the 
spiky structures (Fig. 2A, bottom panel). This observation complements and is 
consistent with the findings reported by Qu et al., who demonstrated that expression 
of a constitutively active PAK4 induces cell rounding and poor adhesion of NIH3T3 
cells (19). The effect of PAK4 on HCC cell migration and invasiveness was further 
confirmed by Transwell migration, wound healing and invasion assays (Fig. 2B-D). 
Complementary to the overexpression, stable knockdown of PAK4 resulted in a 
decrease in the cell mobility (Fig. 2E). 
During the cloning of PAK4, we characterized an exon 2-spliced isoform of 
PAK4 (PAK4β), which exhibits nuclear localization, in contrast to the cytoplasmic 
localization of wildtype PAK4 (PAK4α) (Fig. 3A). The transcript and protein of 
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PAK4β can be observed in a number of HCC cell lines (Supp. Fig. 1A and 5D, 
respectively). Using site-directed mutagenesis, we validated a NES signal located at 
exon 2 and that is important for the nucleo-cytoplasmic shuttling of PAK4α (Fig. 3C). 
Similar finding was reported in a recent study showing that PAK4 is a nucleo-
cytoplasmic shuttling protein (20).  Surprisingly, we noticed that although the IHC 
staining for total PAK4 was mainly localized in cytoplasm, staining for phospho-
PAK4 was mainly in nuclei (Fig. 1C). This result indicated that a subset of 
phosphorylated and potentially activated PAK4 proteins are preferentially 
translocated to the nuclei of HCC cells, but the reason for that remains unknown. It is 
unlikely that the phospho-PAK4 antibody cross-reacted with other Group II PAK 
family members, i.e. PAK5 and PAK6, because both PAK5 and PAK6 expression 
levels were relatively low in the HCC cases examined. Since the S445 site is 
conserved in PAK4β form, we cannot really distinguish whether the nuclear signal of 
phospho-PAK4 is specifically due to the presence of PAK4β form in HCC cells. 
Currently, it still remains unclear whether the PAK4β isoform is exclusively 
expressed in HCC or the nuclear phospho-PAK4 represents a pathological species of 
PAK4 with specific modification. Since the constitutively active mutant of 
PAK4 (S445N) did not confer a nuclear localization pattern of PAK4 protein, the 
possibility that the observed phospho-PAK4 staining in HCC tissue represents a form 
that is recruited by other protein partners or altered by other modifications cannot be 
completely ruled out. Such translocation upon activation has been clearly 
demonstrated by another member of the Group II PAKs PAK6 (21). While the 
importance of nuclear localization of PAK4 is still under speculation, the significance 
of nuclear localization of PAK1 has previously been implicated in breast tumor 
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formation during the transition from ductal hyperplasia to ductal carcinoma in situ and 
then to adenocarcinoma in transgenic mice (22).  
Despite mounting evidence pointing to a role of PAK4 in tumorigenesis, it 
remains unclear how PAK4 overexpression causes carcinogenesis. Recent evidence 
implicates a link between PAK4 and p53 signaling (13), but the detail mechanism for 
the regulation of p53 by PAK4 is largely unknown. Here we provided evidence to 
support that PAK4 phosphorylates and inactivates p53 directly to promote HCC 
metastasis. By means of in vitro kinase, GST affinity pull-down, co-
immunoprecipitation and phospho-specific antibody detection assays (Fig. 4C-F and 
Fig. 5), we demonstrated that PAK4 phosphorylates p53 at serine 215 intracellularly. 
Using wildtype and a nuclear form of PAK4 (PAK4 LVAA), we further demonstrated 
that S215 phosphorylation of p53 significantly diminishes the DNA binding, 
transactivating and tumor suppressive activities of p53 (Fig. 6A-D), suggesting that 
PAK4 is an inhibitory kinase of p53. Given that PAK4 overexpression is associated 
with more metastatic phenotype in clinicopathological analysis, we hypothesized that 
PAK4 phosphorylation of p53 may also play a role in cancer metastasis. Using the 
stable PAK4-phosphorylation defective (S215A) and mimetic (S215D) mutants of 
p53 overexpressing clones, we demonstrated that p53 is able to suppress HCC cell 
migration and invasion, but more surprisingly the S215 phosphorylation of p53 
completely reverts the effect on the suppression of HCC cell migration and invasion 
(Fig. 6F and G). These effects have been observed in at least two HCC cell lines, i.e. 
SMMC-7721 and HLE (Supp. Fig. 4A), indicating that the regulation of p53 by PAK4 
is not cell-line specific. Subsequent analysis using a qRT-PCR array of 84 known 
cancer metastasis-related genes showed that p53 S215D, compared with WT, 
specifically enhances the regulation of several previously uncharacterized p53-
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regulated metastasis genes, including CDH6, CDKN2A, KISS1R, FGFR4 and 
VEGFA, indicating a gain-of-function effect of p53 by PAK4 phosphorylation. It has 
been reported that the S215 site is targeted by Aurora kinase A to inactivate p53 (16). 
A recent study also showed that Aurora kinase B targets the same site to enhance the 
degradation of p53 (23). Currently, it is unclear if PAK4 and Aurora kinases will 
compete with each other for the same site to regulate p53. However, our existing data 
revealed a novel role of p53 in suppressing HCC cell migration and that PAK4 can 
moderate the suppressive effect of p53 through S215 phosphorylation. We believe 
that it will be of interest to explore the interplay between different p53 mutations and 
S215 phosphorylation on the ability to suppress HCC cell migration. Further 
investigation on whether S215 phosphorylation coordinates the cell cycle progression 
and cell migration is currently undergoing.  
We observed that forced expression of PAK4α and PAK4 LVAA protects 
HCC cells from DNA damaging drug-induced cell death (Fig. 6E). Although the 
detailed mechanism for such effect remains to be determined, the fact that PAK4 acts 
as a negative regulator of p53 may present an exciting opportunity to enhance the 
chemo-sensitivity of HCC cells using PAK4 inhibitor in single or combined chemo-
treatment. In summary, we demonstrated the oncogenic properties of PAK4 in HCC 
and provided the first evidence to support an important role of p53 phosphorylation in 
PAK4-mediated cancer metastasis.  
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Figure legends 
Figure 1. Overexpression of PAK4 in HCCs. (A) qRT-PCR results of HCC (T) and 
corresponding nontumorous (NT) liver tissues (59 pairs, P < 0.0001, Wilcoxon 
matched pair test). Horizontal lines represent medians. (B) Representative results of 
Western blotting analysis. Numbers indicate the fold of relative expression (T/NT). (C) 
Representative cases of immunohistochemical staining for PAK4 and phospho-PAK4 
(S474) in HCC (T) and corresponding nontumorous (NT) liver tissues. 
Figure 2. Promotion of HCC cell migration and invasion by PAK4. (A) PAK4 
expression in stable PAK4 overexpressing (PAK4-C1 and -C2) and GFP control 
(GFP-C1 and -C2) SMMC-7721 cells was detected by immunoblotting. (B) Stable 
PAK4 and GFP clones were used for Transwell migration, (C) wounding healing and 
(D) invasion assays. In (B) and (D), *P < 0.05, #P < 0.05.  In (C), *P < 0.04, #P < 
0.04. (E) Stable PAK4 knockdown (Sh-C1 and -C2) and vector control (V-C1 and -C2) 
cells were established in HLE cells and used for Transwell migration assay. Insets: 
Western blotting analysis. *P < 0.02; #P < 0.05. For (B) to (E), one of three 
independent experiments was shown. Scale bar = 100µm. Error bars, mean ± SD of 
samples. t test compared with GFP-C1/V-C1(*) or GFP-C2/V-C2 (#).  
Figure 3. Nuclear localization of PAK4. (A) HeLa cells transfected with constructs 
expressing GFP-PAK4α or GFP-PAK4β were treated with vehicle (Veh) or 
leptomycin B (LMB; 15nM) for 5 hours. Localization of PAK4α or PAK4β was 
identified by the presence of GFP signal (green). Nuclei (blue) were stained with 
DAPI. Scale bar = 20μm. (B) Similar to (A), but transfected with constructs 
expressing GFP-PAK4α or S445N mutant. (C) Similar to (A), but transfected with 
constructs expressing GFP-PAK4α mutants of L82A, V94A or LVAA. (D) HeLa cells 
were transfected with constructs expressing PAK4α or PAK4 LVAA. The 
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cytoplasmic (Cyto) and nuclear (Nu) fractions were extracted for Western blotting 
analysis. 
Figure 4. Phosphorylation of p53 by PAK4. (A) GST-p53 WT and S215A were 
phosphorylated by His-PAK4α in in vitro kinase assay. GST and GST-PAK4tide were 
used as negative and positive controls, respectively. Autoradiography and Coomassie 
blue staining gel (for protein loading) were shown. (B) Schematic diagram of p53 and 
its truncation mutants. TAD: transactivation domain; DBD, DNA-binding domain; 4D, 
tetramerization domain; CTD, C-terminal regulatory domain. (C) Similar to (A), WT 
or mutants of GST-p53 were phosphorylated by His-PAK4α. Autoradiography and 
Coomassie blue staining gel were shown. Asterisks indicate corresponding positions 
of proteins. (D) WT or mutants of GST-p53 and His-PAK4α were used for GST 
affinity pull-down assay. The proteins were detected by immunoblotting. (E) 
HEK293T cells co-transfected with constructs expressing PAK4α or LVAA mutant 
and WT or mutant of p53 were harvested for immunoprecipitation with anti-c-Myc 
agarose conjugate or anti-GFP protein-G Sepharose, and immunoblotting. ms, mouse. 
rb, rabbit. (F) GST-p53 WT or S215A was phosphorylated by His-Aurora A or His-
PAK4α in the in vitro kinase assay. Autoradiography and Coomassie blue staining gel 
were shown. 
Figure 5. Phosphorylation of p53 at the S215 site by PAK4. (A) SMMC-7721 cells 
transfected with constructs expressing PAK4α or LVAA mutant together with p53 
WT or S215A mutant were harvested for immunoprecipitation and Western blotting 
analysis using the anti-phospho-serine and anti-Myc antibodies. Band intensity: p-
serine/total immunoprecipitated p53. Input lysates were analyzed by immunoblotting. 
ms, mouse. rb, rabbit. (B) GST-p53 WT or its mutant carrying serine-to-alanine 
substitution at S215 was phosphorylated by His-Aurora A or His-PAK4α in the in 
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vitro kinase assay. Western blotting analysis was performed. (C) SMMC-7721 cells 
transfected with constructs expressing PAK4α together with p53 WT or S215A 
mutant were harvested for Western blotting with anti-phospho-p53 (S215) and other 
antibodies. The asterisk indicates the p-p53 (S215) protein. Band intensity: p-p53/total 
GFP-p53. Intensity in lane 1 was set as 1. (D) Lysates from HCC, LO2 and 293T cells 
were used for Western blotting analysis with indicated antibodies. The graph shows 
the relative level of PAK4α normalized with β-actin. Level in LO2 was set as 1. 
Lysates from 293T cells transfected with constructs expressing Myc-PAK4α or Myc-
PAKβ were used as positive controls. (E) Stable PAK4 knockdown (Sh-C1 and -C2) 
and vector control (V-C2) HLE cells were harvested for Western blotting analysis. 
Band intensity: p-p53/total p53. Intensity in V-C2 was set as 1. 
Figure 6. Regulation of p53 activity by PAK4 phosphorylation. (A) SMMC-7721 
cells were transfected with constructs expressing p53 WT or mutants for colony 
formation assay. Insets: Western blotting analysis. Vector [pcDNA3.1 (+)] and mock 
transfection (MT) controls were indicated. *P < 0.02 (t test) compared with vector 
control. (B) SMMC-7721 cells were co-transfected with p53-responsive luciferase 
reporter and constructs expressing p53 WT, S215A or S215D mutant together with an 
increasing amount of PAK4α constructs for luciferase reporter assay. Vector and p53 
only were used as negative and positive controls, respectively. Insets: Western 
blotting analysis. *P < 0.04, **P < 0.003, ***P < 0.002 (t test) compared with p53 
only control. (C) SMMC-7721 cells were transfected with p53-responsive luciferase 
reporter together with an increasing amount of PAK4α or LVAA mutant constructs 
for luciferase reporter assay. Vector (pEGFP-C1) was used as negative control. Insets: 
Western blotting analysis for protein expression. *P < 0.05, **P < 0.02 (t test) 
compared with vector control.  (D) Top: HEK293T cells were transfected with 
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constructs of p53 and PAK4α or LVAA mutant. Nuclear lysates were extracted for 
EMSA. Band intensity: p53/oligo complex in lanes 5 and 6 was separately compared 
with lane 4, which the intensity was set as 1. Bottom: Western blotting analysis. (E) 
SMMC-7721 cells were transfected with constructs expressing PAK4α or LVAA 
mutant, and treated with vehicle control (DMSO), cisplatin (CIS; 2µg/ml) or 
etoposide (ETO; 120µM/ml) for 16 hours. A portion of cells was used for colony 
formation assay. Insets: Western blotting analysis with remaining portion. Vector 
(pEGFP-C1) and mock transfection (MT) controls were included. *P < 0.02, **P < 
0.002 (t test) compared with vector control under DMSO treatment. (F) p53 
expression in stable p53 WT, S215A and S215D overexpressing, and GFP control 
SMMC-7721 cells was detected by Western blotting analysis. Stable p53 WT, S215A 
and S215D overexpressing, and GFP control clones were used for Transwell 
migration assay, and (G) invasion assay. *P < 0.0005 (t test) compared with GFP; #P 
< 0.003 with WT or S215A. (H) Stable p53 WT and S215A overexpressing, and GFP 
control clones transiently transfected with constructs expressing PAK4α were used 
for Transwell migration assay. Insets: Western blotting analysis. *P < 0.0002 (t test) 
compared with GFP. Scale bar = 100µm. Error bars, mean ± SD of samples. For (A) 
to (C) and (E) to (H), one of three independent experiments was shown. (I) PAK4 
binds with p53 and phosphorylates p53 at serine 215, which enhances cancer 
metastasis. In the qRT-PCR array, down-regulation (level < 0.5) and up-regulation 
(level > 2) of transcript level of several metastasis-related genes were detected in  
stable p53 S215D overexpressing cells compared with stable p53 WT cells. The genes, 
from top to bottom, are arranged in a descending order of transcript level. *Similar 
level in both stable cell lines of p53 WT and S215A mutant. (J) Lysates from stable 
p53 WT, S215A and S215D mutant, and GFP control SMMC-7721 cells were used 
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for Western blotting analysis. Band intensity: CDH6/β-actin, p14ARF/β-actin or 
KISS1R/β-actin. Intensity in stable GFP control cells was set as 1. 
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Table 1. Clinicopathological correlation of PAK4 overexpression in human HCCs 
Clinicopathological features PAK4  
Overexpression 
(T/NT > 2) 
No overexpression 
(T/NT ≤ 2) P 
Sex   0.521 
Male 29 18  
Female 6 6  
Venous invasion   0.008# 
Absent 11 16  
Present 24 8  
Tumor microsatellites   0.072 
Absent 15 16  
Present 20 8  
Direct liver invasion*^   0.028# 
Absent 19 16  
Present 16 3  
Cellular differentiation (Edmondson grading)^   0.015# 
I–II 10 14  
III–IV 25 9  
HBsAg^   0.322 
Absent 5 6  
Present 29 17  
Tumor encapsulation^   0.050 
Absent 25 10  
Present 10 12  
Tumor size (cm)   0.525 
≤5 13 7  
>5 22 17  
No. of tumor nodules   0.649 
Single 28 18  
Multiple 7 6  
Background liver disease   0.746 
Normal and chronic hepatitis 19 12  
Cirrhosis 16 12  
Tumor pTNM stage^   0.027# 
I-II 10 13  
III-IV 24 9  
*Invasion of tumor to adjacent liver parenchyma 
^With cases having unavailable data 
#P < 0.05 
